Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference
Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference
Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference
阿里拉姆將在派傑投資第36屆年度醫療會議上進行網絡直播演講
Nov 27, 2024
2024年11月27日
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 27, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024 at 11:00 am ET at the Lotte New York Palace Hotel in New York City.
馬薩諸塞州劍橋市--（商業新聞）--2024年11月27日--阿里拉姆製藥公司（納斯達克：ALNY），領先的RNA干擾治療公司，今天宣佈管理層將於2024年12月5日星期四上午11:00在紐約市的紐約大飯店舉行的派傑投資第36屆年度醫療會議上進行公司資料的介紹。
A live audio webcast of the presentation will be available on the Investors section of the Company's website at . A replay will be available on the Alnylam website within 48 hours after the event.
該演講的實時音頻網絡直播將可在公司的投資者網站上獲得。活動結束後48小時內，阿里拉姆網站上將提供重播。
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam's commercial RNAi therapeutic products are ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), and Leqvio (inclisiran), which is being developed and commercialized by Alnylam's partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its "Alnylam P5x25" strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit and engage with us on X (formerly Twitter) at @Alnylam, or on LinkedIn, Facebook, or Instagram.
關於阿里拉姆製藥
阿里拉姆製藥公司（納斯達克：ALNY）領導了RNA干擾（RNAi）向全新一類創新藥物的轉化，具有改變受罕見和普遍疾病困擾的人們生活的潛力，滿足未滿足的需求。 基於諾貝爾獎獲獎科學，RNAi治療代表着一種強大的、經過臨床驗證的方法，產生了變革性的藥物。自2002年成立以來，阿里拉姆領導了RNAi革命，並繼續實現將科學可能性變爲現實的大膽願景。阿里拉姆的商業RNAi治療產品包括ONPATTRO（patirsiran）、AMVUTTRA（vutrisiran）、GIVLAARI（givosiran）、OXLUMO（lumasiran）和Leqvio（inclisiran），後者由阿里拉姆的合作伙伴諾華進行開發和商業化。阿里拉姆擁有一條深厚的研究藥物管線，包括多個處於晚期開發階段的產品候選者。阿里拉姆正在執行其 "Alnylam P5x25" 策略，以通過可持續創新和卓越的財務表現爲全球患者提供轉型藥物，從而建立領先的生物技術形象。阿里拉姆總部位於馬薩諸塞州劍橋市。如需了解更多有關我們的團隊、科學和管線的信息，請訪問並在X（前身爲Twitter）上與我們互動，用戶名爲@Alnylam，或在LinkedIn、Facebook或者Instagram上與我們互動。
View source version on businesswire.com:
在businesswire.com上查看源版本：
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)
617-682-4340
Alnylam Pharmaceuticals, Inc.
克莉絲汀·雷甘·林登布姆
（投資者和媒體）
617-682-4340
Josh Brodsky
(Investors)
617-551-8276
喬什·布羅德斯基
（投資者）
617-551-8276
Source: Alnylam Pharmaceuticals, Inc.
來源：Alnylam Pharmaceuticals，Inc。
譯文內容由第三人軟體翻譯。
